FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 vistas· 09/21/23
OncLive® On Air
OncLive® On Air
0 Suscriptores
0
En

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Mostrar más

 0 Comentarios sort   Ordenar por


Hasta la próxima